Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.57 |
| ▸ | SLC6A12 | P48065 | 3/20 | 0.57 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.57 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CCR3 | P51677 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148249 | 0.95 | DRD2 (0.61) | SIGMAR1SLC6A12TMEM97MCHR1PRKAA2 | |
| SCHEMBL4160333 | 0.83 | PBK (0.47) | ATMPOLB | |
| SCHEMBL4152581 | 0.82 | NPC1 (0.48) | ATM | |
| SCHEMBL4152141 | 0.82 | NPC1 (0.48) | ATM | |
| SCHEMBL4909011 | 0.81 | KDM4E (0.57) | KMT2APOLB | |
| SCHEMBL4160366 | 0.81 | DHODH (0.48) | — | |
| SCHEMBL4153092 | 0.81 | PBK (0.46) | — | |
| SCHEMBL4152149 | 0.78 | PBK (0.54) | MEN1KMT2A | |
| SCHEMBL13778112 | 0.75 | HTR3A (0.46) | — | |
| SCHEMBL4165048 | 0.75 | PBK (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | claimed |
| EP-1984370-A1 | IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Crystalgenomics, Inc. (KR) | 2008-10-29 | — | — | EP | claimed |
| WO-2007083978-A1 | IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | CRYSTALGENOMICS, INC. (KR) | 2007-07-26 | — | — | WO | claimed |
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | disclosed |
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | disclosed |
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | YUYU PHARMA, INC. (KR) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170847-A1 | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same | GSK3B, GSK3A, MAP3K3 | SIGMAR1 2489/4885SLC6A12 4733/4885TMEM97 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.